Nicardipine HCl

製品コードS4181 バッチS418102

印刷

化学情報

Synonyms

RS-69216,YC-93

Storage
(From the date of receipt)

3 years -20°C powder
1 years -80°C in solvent

化学式

C₂₆H₂₉N₃O₆.HCl

分子量

515.99

CAS No.

54527-84-3

Solubility (25°C)*

体外

DMSO

100 mg/mL (193.8 mM)

Water

Insoluble

Ethanol

Insoluble

体内（毎回新しく調製した物を用意してください）

Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O この製剤はselleckのラボで検証済みです。上記の溶解方法がご要望を満たさない場合、selleckの営業担当までお問い合わせ頂ければ、個別の試験を行います。	5mg/ml (9.69mM)	Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil この製剤はselleckのラボで検証済みです。上記の溶解方法がご要望を満たさない場合、selleckの営業担当までお問い合わせ頂ければ、個別の試験を行います。	0.71mg/ml (1.38mM)	Taking the 1 mL working solution as an example, add 50 μL of 14.2 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明	Nicardipine HCl（RS-69216、YC-93）は、血管疾患の治療に使用されるジヒドロピリジン系のカルシウムチャネル遮断薬です。
in vivo	Nicardipine (100 mg/kg) produces a significant transient decrease in retinal blood flow in cats. Nicardipine (100 mg/kg) produces a significant increase in ONH blood flow despite a significant decrease of the mean arterial blood pressure in cats, which suggests that nicardipine could have a beneficial effect on ONH tissue. Nicardipine significantly reduces systolic pressure in the spontaneously hypertensive rats (SHR). Nicardipine significantly reduces the thickness of the tunica media, the media: lumen ratio and increases the luminal area, primarily at the level of small pial arteries and of intracerebral arteries in the spontaneously hypertensive rats (SHR). Nicardipine increases the number of neurones in the frontal cortex and in the occipital cortex of SHR and counters hyperplasia and hypertrophy of GFAP-immunoreactive astrocytes. Nicardipine increases the number of neurones in the CA1 field of the hippocampus and decreases the number and the size of astrocytes of the white matter and grey matter, respectively. Nicardipine (40 mg/kg twice daily for 8 weeks) reduces plaque area by 49.2% in cholesterol-fed rabbits. Nicardipine (40 mg/kg) reduces cholesterol accumulation in the aortic arch by 74.5% in cholesterol-fed rabbits. Nicardipine (5 mg/kg) combined with Nimodipine (80 mg/kg) and Flunarizine(80 mg/kg) results in a significant enhancement of the protective potency of either ethosuximide (50 mg/kg) or valproate (100 mg/kg) against clonic seizures in mice.

製品説明

Nicardipine HCl（RS-69216、YC-93）は、血管疾患の治療に使用されるジヒドロピリジン系のカルシウムチャネル遮断薬です。

in vivo

Nicardipine (100 mg/kg) produces a significant transient decrease in retinal blood flow in cats. Nicardipine (100 mg/kg) produces a significant increase in ONH blood flow despite a significant decrease of the mean arterial blood pressure in cats, which suggests that nicardipine could have a beneficial effect on ONH tissue. Nicardipine significantly reduces systolic pressure in the spontaneously hypertensive rats (SHR). Nicardipine significantly reduces the thickness of the tunica media, the media: lumen ratio and increases the luminal area, primarily at the level of small pial arteries and of intracerebral arteries in the spontaneously hypertensive rats (SHR). Nicardipine increases the number of neurones in the frontal cortex and in the occipital cortex of SHR and counters hyperplasia and hypertrophy of GFAP-immunoreactive astrocytes. Nicardipine increases the number of neurones in the CA1 field of the hippocampus and decreases the number and the size of astrocytes of the white matter and grey matter, respectively. Nicardipine (40 mg/kg twice daily for 8 weeks) reduces plaque area by 49.2% in cholesterol-fed rabbits. Nicardipine (40 mg/kg) reduces cholesterol accumulation in the aortic arch by 74.5% in cholesterol-fed rabbits. Nicardipine (5 mg/kg) combined with Nimodipine (80 mg/kg) and Flunarizine(80 mg/kg) results in a significant enhancement of the protective potency of either ethosuximide (50 mg/kg) or valproate (100 mg/kg) against clonic seizures in mice.

プロトコル(参考用のみ)

参考

https://pubmed.ncbi.nlm.nih.gov/1526739/
https://pubmed.ncbi.nlm.nih.gov/9120663/
https://pubmed.ncbi.nlm.nih.gov/3994582/

https://pubmed.ncbi.nlm.nih.gov/8872866/

+ 展开

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Computational drug repurposing in Parkinsons disease: Omaveloxolone and cyproheptadine as promising therapeutic candidates [ Frontiers in Pharmacology, 2025, 1539032]	PubMed: 40264664
Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension [ Cell Discov, 2020, 6(1):96]	PubMed: 33349633
Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension [ Cell Discovery, 2020, 96]	PubMed: 33349633
High-Throughput Screening of an FDA-Approved Drug Library Identifies Inhibitors against Arenaviruses and SARS-CoV-2 [ ACS Infect Dis, 2020, acsinfecdis.0c00486]	PubMed: 33183004

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。